FR08C0041I2 - - Google Patents

Info

Publication number
FR08C0041I2
FR08C0041I2 FR08C0041C FR08C0041C FR08C0041I2 FR 08C0041 I2 FR08C0041 I2 FR 08C0041I2 FR 08C0041 C FR08C0041 C FR 08C0041C FR 08C0041 C FR08C0041 C FR 08C0041C FR 08C0041 I2 FR08C0041 I2 FR 08C0041I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR08C0041C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6530833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR08C0041(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BASF SE filed Critical BASF SE
Publication of FR08C0041I1 publication Critical patent/FR08C0041I1/fr
Application granted granted Critical
Publication of FR08C0041I2 publication Critical patent/FR08C0041I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/20—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with no nitrogen atoms directly attached to a ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
FR08C0041C 1994-10-14 2008-10-21 Active FR08C0041I2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4436851 1994-10-14
DE19533023A DE19533023B4 (de) 1994-10-14 1995-09-07 Neue Carbonsäurederivate, ihre Herstellung und Verwendung
PCT/EP1995/003963 WO1996011914A1 (de) 1994-10-14 1995-10-07 Neue carbonsäurederivate, ihre herstellung und verwendung

Publications (2)

Publication Number Publication Date
FR08C0041I1 FR08C0041I1 (es) 2008-11-28
FR08C0041I2 true FR08C0041I2 (es) 2009-12-18

Family

ID=6530833

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0041C Active FR08C0041I2 (es) 1994-10-14 2008-10-21

Country Status (32)

Country Link
US (15) USRE42462E1 (es)
EP (2) EP0785926B1 (es)
JP (6) JP3957748B2 (es)
KR (1) KR100438339B1 (es)
CN (3) CN1293059C (es)
AT (2) ATE204568T1 (es)
BR (1) BR9509338A (es)
CA (1) CA2201785C (es)
CZ (1) CZ294603B6 (es)
DE (4) DE19533023B4 (es)
DK (1) DK0785926T3 (es)
ES (2) ES2162942T3 (es)
FI (1) FI120492B (es)
FR (1) FR08C0041I2 (es)
GR (1) GR3036931T3 (es)
HK (2) HK1066541A1 (es)
HR (2) HRP950517B1 (es)
HU (1) HU220621B1 (es)
IL (1) IL115560A (es)
LU (1) LU91487I2 (es)
MX (1) MX9702658A (es)
NL (1) NL300361I2 (es)
NO (2) NO308846B1 (es)
NZ (1) NZ294849A (es)
PL (1) PL186850B1 (es)
PT (1) PT785926E (es)
RU (1) RU2180335C2 (es)
SI (1) SI9520110A (es)
TW (1) TW577880B (es)
UA (1) UA45985C2 (es)
WO (1) WO1996011914A1 (es)
ZA (1) ZA958642B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19536891A1 (de) * 1995-10-04 1997-04-10 Basf Ag Neue Aminosäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
CA2275256A1 (en) 1996-12-18 1998-06-25 Basf Aktiengesellschaft Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
JP2001514254A (ja) * 1997-09-04 2001-09-11 ビーエーエスエフ アクチェンゲゼルシャフト 新規カルボン酸誘導体、その製造及び混合ｅｔａ／ｅｔｂエンドセリン受容体拮抗薬としてのその使用
ATE257706T1 (de) * 1997-09-26 2004-01-15 Abbott Gmbh & Co Kg Endothelin antagonist und renin-angiotensin system hemmer als kombinationspräparate
DE19743142A1 (de) * 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19743143A1 (de) * 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19743681A1 (de) * 1997-10-02 1999-04-08 Knoll Ag Methode zur Verhinderung der Transplantatabstoßung
SK4592000A3 (en) * 1997-10-31 2000-12-11 Basf Ag Novel carboxylic acid derivatives which carry amide side chains, production of said carboxylic acid derivatives and their use as endothelin receptor antagonists
DE19750529A1 (de) * 1997-11-14 1999-05-20 Basf Ag Neue heterocyclisch substituierte alpha-Hydroxycarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
DE19809635A1 (de) * 1998-03-06 1999-09-09 Basf Ag Verfahren zur Darstellung von Endothelinrezeptorantagonisten vom Sulfanyltyp
DE19850301A1 (de) 1998-10-30 2000-05-04 Basf Ag Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
DE10002393A1 (de) 2000-01-20 2001-07-26 Basf Ag Verfahren zur enantioselektiven Herstellung von 3,3-Diphenyl-2,3-epoxypropionsäureestern
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
WO2002064573A1 (de) * 2001-02-14 2002-08-22 Abbott Gmbh & Co. Kg Neue carbonsäurederivate mit alkylsubstituierten triazinen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
EP1243263B1 (en) 2001-03-21 2002-11-27 Schwarz Pharma Ag Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
US6772708B2 (en) * 2001-10-30 2004-08-10 The Procter And Gamble Company Wetness indicator having improved colorant retention
DE10259382A1 (de) * 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung
US20040204422A1 (en) * 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
SG153831A1 (en) 2004-03-17 2009-07-29 Novartis Ag Use of renin inhibitors in therapy
WO2005099740A1 (en) 2004-04-16 2005-10-27 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
BRPI0514721A (pt) 2004-08-27 2008-06-24 Sanol Arznei Schwarz Gmbh uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
DE102005025161A1 (de) * 2005-06-01 2006-12-07 Phenion Gmbh & Co. Kg Derivate des Pyrimidins und Triazins und deren Verwendung
US8067621B2 (en) * 2006-01-20 2011-11-29 Schering Corporation Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
BRPI0709950A2 (pt) * 2006-04-13 2011-08-02 Actelion Pharmaceuticals Ltd uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin
TWI397417B (zh) 2006-06-15 2013-06-01 Ucb Pharma Gmbh 具有協同抗驚厥功效之醫藥組成物
JP2010512414A (ja) 2006-12-12 2010-04-22 ギリード・コロラド・インコーポレーテッド 肺高血圧を処置するための組成物
EP2118073A2 (en) 2007-02-02 2009-11-18 Concert Pharmaceuticals Inc. Selective endothelin type-a antagonists
JP2010535210A (ja) * 2007-07-31 2010-11-18 ギリード・コロラド・インコーポレーテッド アンブリセンタンの代謝産物および誘導体
US20090069353A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched ambrisentan
DE102008037324A1 (de) 2008-08-11 2010-02-18 Ratiopharm Gmbh Pharmazeutische Formulierung zur pulmonalen Blutdrucksenkung
WO2010070658A2 (en) * 2008-11-05 2010-06-24 Msn Laboratories Limited Improved process for the preparation of endothelin receptor antagonists
WO2010091877A2 (en) 2009-02-13 2010-08-19 Ratiopharm Gmbh Process for producing ambrisentan
DE202009009917U1 (de) 2009-07-21 2010-02-11 Ratiopharm Gmbh Ambrisentan in spezifischer kristalliner Form
WO2011004402A2 (en) 2009-07-10 2011-01-13 Cadila Healthcare Limited Improved process for the preparation of ambrisentan and novel intermediates thereof
WO2011022694A2 (en) * 2009-08-20 2011-02-24 University Of Tennessee Research Foundation, The Furanopyrimidine cannabinoid compounds and related methods of use
IN2012DN05028A (es) 2009-12-07 2015-10-23 Univ Johns Hopkins
EP2509941B1 (en) * 2009-12-07 2019-01-23 The Johns Hopkins University N-acylated hydroxylamine derivatives and o-acylated hydroxylamine derivatives
KR20130054250A (ko) 2010-03-15 2013-05-24 낫코 파마 리미티드 매우 순수한 암브리센탄의 제조를 위한 방법
US20130184490A1 (en) * 2010-08-04 2013-07-18 Natco Pharma Limited Process to prepare s-2-hydroxy-3-methoxy-3,3-diphenyl propionic acid
NZ610012A (en) 2010-10-15 2015-05-29 Gilead Sciences Inc Compositions and methods of treating pulmonary hypertension
EP2476670A1 (en) 2011-01-07 2012-07-18 Zentiva, K.S. Stable solid salts of ambrisentan
CN102276536B (zh) 2011-06-10 2015-04-29 中国科学院化学研究所 一种光学纯的(+)-安倍生坦和光学纯的(+)-达芦生坦的制备方法
CN103012280B (zh) * 2011-09-22 2015-04-29 江苏康缘药业股份有限公司 一种制备安立生坦的方法
KR101855506B1 (ko) 2011-10-13 2018-05-08 주식회사 동진쎄미켐 방향족 고리 함유 고분자 및 이를 포함하는 레지스트 하층막 조성물
WO2013057468A1 (en) 2011-10-19 2013-04-25 Cipla Limited Process for the preparation of an endothelin receptor antagonist
PL2867214T3 (pl) 2012-06-29 2017-02-28 Kern Pharma, S.L. Sposób wytwarzania pochodnych kwasów karboksylowych i ich związków pośrednich
CN103524424A (zh) * 2012-07-04 2014-01-22 天津药物研究院 一种安立生坦的晶型vi及其制备方法和应用
CN103524425A (zh) * 2012-07-04 2014-01-22 天津药物研究院 一种安立生坦的晶型v及其制备方法和应用
CN104098462B (zh) * 2013-04-12 2017-11-17 江苏豪森药业集团有限公司 2‑羟基‑3‑甲氧基‑3,3‑二苯基丙酸消旋物的拆分方法
CN104592129B (zh) * 2013-10-30 2019-04-16 武汉启瑞药业有限公司 一种改进的制备安立生坦的方法
CN103709106A (zh) * 2013-12-06 2014-04-09 石家庄博策生物科技有限公司 一种立体选择性制备安立生坦的方法
CN104744231A (zh) * 2013-12-26 2015-07-01 天津药物研究院 一种拆分2-羟基丙酸消旋体的方法
CN105801404B (zh) * 2014-12-31 2019-01-08 辽宁远大诺康生物制药有限公司 一种s-2-羟基-3-甲氧基-3,3-二苯基丙酸及其制备方法
CN106699626B (zh) * 2015-11-13 2019-08-16 辽宁远大诺康生物制药有限公司 一种2-羟基-3-甲氧基-3,3-二苯基丙酸盐消旋体的制备方法
EP3235496A1 (en) 2016-04-19 2017-10-25 Noorik Biopharmaceuticals AG Treatment of acute renal failure
CN109705042B (zh) * 2017-10-26 2021-12-21 正大天晴药业集团股份有限公司 一种安立生坦的制备方法
WO2024092240A1 (en) 2022-10-28 2024-05-02 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE403578C (de) 1924-10-02 Walter Beige Verfahren zum Innen-Emaillieren von Roehren
JPS5729445B2 (es) 1974-06-25 1982-06-23
GB8912700D0 (en) 1989-06-02 1989-07-19 Shell Int Research Herbicidal compounds
JP2771604B2 (ja) * 1988-06-20 1998-07-02 クミアイ化学工業株式会社 除草剤及びその有効成分となる新規なアルカン酸誘導体
DE68914197T2 (de) * 1988-06-20 1994-11-10 Kumiai Chemical Industry Co Alkansäurederivate und herbizide Mittel.
JPH0331266A (ja) 1989-06-27 1991-02-12 Nissan Chem Ind Ltd ピリミジン誘導体及び除草剤
US5270289A (en) 1989-07-19 1993-12-14 Schering Aktiengesellschaft Herbicidal dimethoxy pyrimidinyloxy-fluorinated acids and salts
IL94999A (en) 1989-07-19 1994-10-07 Schering Ag History of Acid (A-pyrimidinyloxy) Theo (and A-triazinyloxy) Theo (carboxylic, and herbicides containing them)
FR2650365B1 (fr) 1989-07-28 1991-11-22 Caillau Ets Raccord rapide
JPH03240777A (ja) 1990-02-20 1991-10-28 Ube Ind Ltd 脂肪酸誘導体、その製造法及び除草剤
DE4029648A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 4-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
JPH05125058A (ja) * 1990-10-19 1993-05-21 Ube Ind Ltd ３−アルコキシアルカン酸化合物、その中間体、その製造法及び除草剤
CA2053603A1 (en) 1990-10-19 1992-04-20 Katsumasa Harada 3-alkoxyalkanoic acid derivative, process for preparing the same and herbicide using the same
DE4035758A1 (de) 1990-11-08 1992-05-14 Schering Ag Substituierte (alpha)-pyrimidinyloxy(thio)- und (alpha)-triazinyloxy(thio)-carbonsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung
JP2730021B2 (ja) 1991-05-31 1998-03-25 宇部興産株式会社 ３−ベンジルオキシアルカン酸誘導体、その製造法及び除草剤
EP0517215B1 (en) * 1991-06-07 1998-09-02 Ube Industries, Ltd. Pyrimidine or triazine derivative, process for preparing the same and herbicide using the same
JP2730022B2 (ja) * 1991-06-07 1998-03-25 宇部興産株式会社 ３−アルコキシブチリルイミダゾール誘導体、その製造法及び除草剤
DE4123469A1 (de) 1991-07-16 1993-01-21 Basf Ag Herbizide mittel, die n-dichloracetyl-diazacycloalkane als antagonistische verbindungen enthalten
WO1993012094A1 (de) * 1991-12-10 1993-06-24 Hoechst Schering Agrevo Gmbh Pyrimidinyl- oder triazinyl-oxy-(oder -thio)-aldehydderivate, und verwendung als herbizide oder pflanzenwachstumsregulatoren
DE4142570A1 (de) 1991-12-21 1993-06-24 Basf Ag Glykolaldehyd- und milchsaeurederivate, deren herstellung und verwendung
DE4201875A1 (de) 1992-01-24 1993-07-29 Basf Ag Thiocarbonsaeurederivate, verfahren und zwischenprodukte zu ihrer herstellung
US5376620A (en) 1992-04-17 1994-12-27 Ube Industries, Ltd. Sulfonamide derivative, process for preparing the same and herbicide using the same
WO1993025540A1 (en) * 1992-06-17 1993-12-23 Ciba-Geigy Ag Pyrimidinyl-and triazinyl compounds with herbicidal activity
US5541148A (en) 1992-07-08 1996-07-30 Ciba-Geigy Corporation Selective safened herbicidal composition comprising 2-ethoxycarbonyl-3-(4,6-dimethoxypyrimidine-2-yl) oxy-pyridine and an acylsulfamoylphenyl-urea safener
EP0671880A1 (en) 1992-07-08 1995-09-20 Ciba-Geigy Ag Selective herbicidal composition
JP2985992B2 (ja) 1992-07-21 1999-12-06 宇部興産株式会社 ３−アルコキシ−ｎ−シクロアルキルスルホニルアルカン酸アミド誘導体、その製造法及び除草剤
DE4313413A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryloxy(thio)-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
DE4313412A1 (de) * 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
EP0627472B1 (en) * 1993-06-03 2000-03-08 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Curable composition
DE4335950A1 (de) 1993-10-21 1995-04-27 Basf Ag Derivate von 3-Hydroxycarbonsäuren, deren Herstellung und Verwendung
DE4411225A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
WO1996000219A1 (en) 1994-06-27 1996-01-04 Ciba-Geigy Ag Pyrimidinyl- and triazinyl-oxy and thio-3-haloalkyl-propionic acid derivatives as herbicides
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
ES2148578T3 (es) 1994-10-21 2000-10-16 Glaxo Wellcome Inc Soporte de medicamento para un inhalador de polvo seco y procedimiento de fabricacion del mismo.
US6030975A (en) 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
ATE257706T1 (de) 1997-09-26 2004-01-15 Abbott Gmbh & Co Kg Endothelin antagonist und renin-angiotensin system hemmer als kombinationspräparate
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19754082A1 (de) 1997-12-05 1999-06-10 Knoll Ag Methode zur Bekämpfung der Fettleibigkeit
DE19850301A1 (de) 1998-10-30 2000-05-04 Basf Ag Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren
DE10002393A1 (de) 2000-01-20 2001-07-26 Basf Ag Verfahren zur enantioselektiven Herstellung von 3,3-Diphenyl-2,3-epoxypropionsäureestern
EP1946502B2 (en) 2006-07-12 2017-09-13 Huawei Technologies Co., Ltd. Method for controlling congestion
JP2010535210A (ja) 2007-07-31 2010-11-18 ギリード・コロラド・インコーポレーテッド アンブリセンタンの代謝産物および誘導体

Also Published As

Publication number Publication date
JP4787184B2 (ja) 2011-10-05
CN1923820A (zh) 2007-03-07
NZ294849A (en) 1999-04-29
ZA958642B (en) 1997-04-14
NO2008015I1 (no) 2008-11-03
CN1293059C (zh) 2007-01-03
JP2007137892A (ja) 2007-06-07
HK1104293A1 (en) 2008-01-11
ES2162942T3 (es) 2002-01-16
NL300361I1 (nl) 2008-12-01
US5969134A (en) 1999-10-19
NO2008015I2 (no) 2012-03-05
CZ113297A3 (cs) 1998-03-18
US7109205B2 (en) 2006-09-19
AU3804595A (en) 1996-05-06
HRP20040364B1 (en) 2006-09-30
TW577880B (en) 2004-03-01
JP5700378B2 (ja) 2015-04-15
CN1513844A (zh) 2004-07-21
JP4512106B2 (ja) 2010-07-28
DE19533023B4 (de) 2007-05-16
US7119097B2 (en) 2006-10-10
PL319655A1 (en) 1997-08-18
US20060160808A1 (en) 2006-07-20
UA45985C2 (uk) 2002-05-15
US20020052495A1 (en) 2002-05-02
PL186850B1 (pl) 2004-03-31
US20060276474A1 (en) 2006-12-07
EP0785926B1 (de) 2001-08-22
ATE204568T1 (de) 2001-09-15
EP0785926A1 (de) 1997-07-30
JP2012111772A (ja) 2012-06-14
JP2007126488A (ja) 2007-05-24
ATE277911T1 (de) 2004-10-15
CN1923820B (zh) 2010-04-21
NL300361I2 (nl) 2009-02-02
NO971675D0 (no) 1997-04-11
CN1142918C (zh) 2004-03-24
US20100076188A1 (en) 2010-03-25
CA2201785A1 (en) 1996-04-25
US8349843B2 (en) 2013-01-08
EP1110952A1 (de) 2001-06-27
ES2226996T3 (es) 2005-04-01
CA2201785C (en) 2006-08-29
JP2007169295A (ja) 2007-07-05
US20060276645A1 (en) 2006-12-07
GR3036931T3 (en) 2002-01-31
IL115560A0 (en) 1996-01-19
US20110178294A1 (en) 2011-07-21
DE122008000049I1 (de) 2009-01-29
US20040092742A1 (en) 2004-05-13
HRP950517A2 (en) 1997-10-31
CN1160396A (zh) 1997-09-24
JPH10507190A (ja) 1998-07-14
HRP20040364A2 (en) 2005-06-30
US7601730B2 (en) 2009-10-13
US7863445B2 (en) 2011-01-04
HK1066541A1 (en) 2005-03-24
US6197958B1 (en) 2001-03-06
US20120088911A1 (en) 2012-04-12
MX9702658A (es) 1997-06-28
JP2007137893A (ja) 2007-06-07
EP1110952B9 (de) 2004-12-15
FI971529A (fi) 1997-04-11
LU91487I2 (fr) 2008-12-15
FI971529A0 (fi) 1997-04-11
FR08C0041I1 (es) 2008-11-28
USRE42462E1 (en) 2011-06-14
IL115560A (en) 2003-02-12
AU688611B2 (en) 1998-03-12
DE59510949D1 (de) 2004-11-04
US20130317044A1 (en) 2013-11-28
WO1996011914A1 (de) 1996-04-25
DE19533023A1 (de) 1996-04-18
RU2180335C2 (ru) 2002-03-10
JP3957748B2 (ja) 2007-08-15
BR9509338A (pt) 1997-11-04
PT785926E (pt) 2002-02-28
NO308846B1 (no) 2000-11-06
EP1110952B1 (de) 2004-09-29
DK0785926T3 (da) 2001-10-08
FI120492B (fi) 2009-11-13
US5932730A (en) 1999-08-03
KR100438339B1 (ko) 2004-08-25
US7582647B2 (en) 2009-09-01
KR970707103A (ko) 1997-12-01
US6600043B2 (en) 2003-07-29
JP5160797B2 (ja) 2013-03-13
SI9520110A (en) 1997-12-31
US20070203338A1 (en) 2007-08-30
HU220621B1 (hu) 2002-03-28
USRE42477E1 (en) 2011-06-21
HUT77443A (hu) 1998-04-28
DE59509541D1 (de) 2001-09-27
JP4512105B2 (ja) 2010-07-28
HRP950517B1 (en) 2004-06-30
NO971675L (no) 1997-06-10
CZ294603B6 (cs) 2005-02-16

Similar Documents

Publication Publication Date Title
TW267938B (es)
FR08C0041I2 (es)
DK105996A (es)
EP0666525A3 (es)
DK0677466T3 (es)
EP0671407A3 (es)
TW283689B (es)
EP0666470A3 (es)
TW278307B (es)
EP0665261A3 (es)
TW271528B (es)
EP0667387A3 (es)
DE69535748D1 (es)
EP0671446A3 (es)
TW271479B (es)
EP0670326A3 (es)
TW276344B (es)
EP0681204A3 (es)
EP0667627A3 (es)
FR2727997B1 (es)
IN178719B (es)
IN177530B (es)
CU22453A3 (es)
EP0806635A4 (es)
EP0669619A3 (es)